☆ 4.7 Article

Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers

VACCINES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Wilfredo F. Garcia-Beltran et al.

Summary: Recent surveillance has identified the emergence of the SARS-CoV-2 Omicron variant, which carries up to 36 mutations in the spike protein and has the potential to evade vaccine-induced immunity. This study found that individuals vaccinated with mRNA vaccines exhibited strong neutralization of the Omicron variant, while most vaccinees had weak neutralization. The study also revealed that the Omicron variant infects more efficiently than other tested variants.

CELL (2022)

添加到收藏夹

Article Immunology

Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies

Saathvik R. Kannan et al.

Summary: The Omicron variant of concern (VOC) has a large number of mutations, with 46 high prevalence mutations, which may affect the binding affinities of antibodies to the S protein.

JOURNAL OF AUTOIMMUNITY (2022)

添加到收藏夹

Article Virology

An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey

Derya Caglayan et al.

Summary: This study evaluated the antibody levels after CoronaVac vaccination and heterologous/homologous booster administration among healthcare workers in Turkey. The results showed a decline in antibody levels over time, with a reduction of 61.4% or more in some participants. Chronic disease and the age group of 36-50 were identified as predictors for low antibody response. Participants who received the BNT162b2 vaccine showed a 104.8-fold increase in antibody levels.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens et al.

Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.

LANCET (2022)

添加到收藏夹

Article Infectious Diseases

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng et al.

Summary: The study showed that a two-dose schedule of CoronaVac generated good immune response in adults, and a third dose given 8 months after the second dose effectively recalled specific immune responses to SARS-CoV-2, leading to a remarkable increase in antibody concentration. This indicates that the two-dose schedule provides good immune memory, and a primary third dose given 2 months after the second dose induced slightly higher antibody titres than the primary two doses.

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Sandile Cele et al.

Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.

NATURE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

Jinyan Liu et al.

Summary: This study demonstrates that cellular immunity induced by current SARS-CoV-2 vaccines is highly conserved to the Omicron spike protein. Individuals vaccinated with Ad26.COV2.S or BNT162b2 vaccines showed durable spike-specific CD8(+) and CD4(+) T cell responses that were cross-reactive to both the Delta and Omicron variants, including in central and effector memory cellular subpopulations.

NATURE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Eddy Perez-Then et al.

Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.

NATURE MEDICINE (2022)

添加到收藏夹

Article Immunology

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults

Ritthideach Yorsaeng et al.

Summary: The immune response after the AZD1222 booster in individuals who received the two-dose CoronaVac vaccine was found to be limited, with lower neutralizing activity against the wild type and variants. However, the AZD1222 booster significantly enhanced the immune response, resulting in higher antibody levels and neutralizing activity.

VACCINE (2022)

添加到收藏夹

Article Immunology

Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial

Simon Jochum et al.

Summary: This study assessed the clinical utility of the Roche Elecsys Anti-SARS-CoV-2 S assay in evaluating the immune response after mRNA-1273 vaccination. The results suggest that ACOV2S can be used to quantitatively assess vaccine-induced SARS-CoV-2 antibodies and may indicate the presence of neutralizing antibodies.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Cell Biology

Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine

Yihao Liu et al.

Summary: SARS-CoV-2 inactivated vaccines have demonstrated significant efficacy in reducing severe illness and death. Despite a decline in humoral immunity over time, memory B and T cells remain detectable and can provide a quick recall response. A third booster dose enhances the immune response and improves the durability of protective immunity. Additionally, healthcare workers with low serological response to two doses still possess immune memory that can be quickly recalled by a third dose.

CELL DISCOVERY (2022)

添加到收藏夹

Article Immunology

Peculiarities of the T Cell Immune Response in COVID-19

Dmitry Kudlay et al.

Summary: Understanding the immune response to SARS-CoV-2, especially the T cell response, is crucial for vaccine development and disease control strategies. This review summarizes studies on the immune response to coronavirus infections, provides insights into T cell components, and presents the most informative methods for assessing the immune response to SARS-CoV-2 infection.

VACCINES (2022)

添加到收藏夹

Article Immunology

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

Sitthichai Kanokudom et al.

Summary: This study evaluated the booster effect of different vaccine platforms in healthy adults who had received a full dose of inactivated vaccine. The viral vector and mRNA vaccine boosters showed greater immunogenicity compared to the inactivated vaccine. In addition, the vaccinated serum had a high neutralization activity against SARS-CoV-2 wild-type and variants.

VACCINES (2022)

添加到收藏夹

Article Immunology

Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers

Wisit Prasithsirikul et al.

Summary: This study evaluated the immunogenicity of ChAdOx1 nCoV-19 as a third dose vaccine in healthcare workers who previously received two shots of CoronaVac. The results showed a significant improvement in immunity one month after vaccination. Subgroup analysis indicated a more significant improvement in neutralizing antibodies in the population with negative anti-spike IgG at baseline.

VACCINES (2022)

添加到收藏夹

Editorial Material Infectious Diseases

WHO international standard for SARS-CoV-2 antibodies to determine markers of protection

Feng Zhu et al.

LANCET MICROBE (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine

Thuy Trang Nguyen et al.

Summary: This study assessed the reactogenicity and immunogenicity of heterologous COVID-19 vaccination regimens and found that these regimens showed higher immunogenicity and tolerable reactogenicity. Additionally, they provided potential protection against the variant of concern, including the Delta variant.

BIOMEDICINE & PHARMACOTHERAPY (2022)

添加到收藏夹

Letter Virology

SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen

Ali Umit Keskin et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Roanne Keeton et al.

Summary: Despite reduced neutralizing antibody activity, T cell responses induced by vaccination or infection can cross-recognize the Omicron variant and provide protection.

NATURE (2022)

添加到收藏夹

Article Allergy

Short-term immune response after inactivated SARS-CoV-2 (CoronaVac?, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria?, Oxford-AstraZeneca) vaccinations in health care workers

Watsamon Jantarabenjakul et al.

Summary: This study found that the short-term immune response varied in healthcare workers after receiving inactivated SARS-CoV-2 and ChAdOx1 nCoV-19 vaccines. The immune response declined rapidly after the inactivated vaccine, indicating the need for booster doses.

ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

添加到收藏夹

Article Immunology

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Jianmin Zuo et al.

Summary: The study shows that functional SARS-CoV-2-specific T cell responses are retained and robust at 6 months following infection, with higher T cell responses observed in donors who had experienced symptomatic infection. Levels of nucleoprotein-specific T cells were correlated with nucleoprotein-specific antibody levels, providing insights into the persistence and correlation of immune responses.

NATURE IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Qian He et al.

Summary: Our study demonstrated that utilizing a heterologous prime-boost strategy with different combinations of COVID-19 vaccine candidates can enhance neutralizing antibody levels and T cell responses, providing new insights for vaccine development and application in controlling the SARS-CoV-2 pandemic.

EMERGING MICROBES & INFECTIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu et al.

Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 Variants and Vaccines

Philip R. Krause et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity

Alexander A. Lehmann et al.

Summary: SARS-CoV-2 infection may not induce a durable antibody response in all infected individuals, leading researchers to focus on specific T cell memory against the virus.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Manish Sadarangani et al.

Summary: Most COVID-19 vaccines aim to induce immune responses, particularly neutralizing antibodies (NAbs), against the spike protein of the virus. mRNA vaccines have shown efficacy after just one dose, while adenovirus vaccines elicit polyfunctional antibodies and strong T cell responses. These findings suggest that protection may not solely rely on NAbs but also involve other immune effector mechanisms.

NATURE REVIEWS IMMUNOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Julian Braun et al.

NATURE (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Chee Wah Tan et al.

NATURE BIOTECHNOLOGY (2020)

添加到收藏夹

Article Biochemical Research Methods

Neutralization assays for differential henipavirus serology using Bio-Plex Protein Array Systems

Katharine N. Bossart et al.

JOURNAL OF VIROLOGICAL METHODS (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.